BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.
At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets. The company has assembled a diversified pipeline of preclinical and early-stage clinical programs spanning immuno-oncology, inflammatory diseases, metabolic disorders and fibrotic conditions. Its lead programs are advancing through proof-of-concept studies designed to demonstrate the potential to modulate age-related pathways and produce durable clinical benefits.
Founded in 2015 and headquartered in South San Francisco, California, BioAge Labs operates a research and development facility in the San Francisco Bay Area and collaborates with academic institutions and contract research organizations worldwide. Since its inception, the company has secured multiple partnerships to expand its target discovery efforts and accelerate translational research. BioAge completed its public listing via merger with a special purpose acquisition company in early 2021, positioning it to fund ongoing clinical development and platform expansion.
BioAge is led by President and Chief Executive Officer Michael A. Duncan, who brings extensive experience in biotech leadership, strategic partnerships and capital markets. The company’s scientific strategy is guided by co-founder and Chief Scientific Officer Kristen Fortney, Ph.D., along with a management team experienced in drug discovery, clinical development and regulatory affairs. Together, they aim to translate aging biology insights into medicines that improve health outcomes for aging populations.
AI Generated. May Contain Errors.
Free BIOA Stock Alerts